MediWound (NASDAQ:MDWD) Earns Buy Rating from HC Wainwright

MediWound (NASDAQ:MDWD)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $28.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 67.16% from the stock’s current price.

A number of other analysts also recently weighed in on MDWD. Maxim Group upped their price target on shares of MediWound from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, July 16th. StockNews.com upgraded MediWound to a “sell” rating in a research note on Monday, August 5th.

MediWound Price Performance

MediWound stock opened at $16.75 on Friday. The stock’s fifty day moving average price is $17.62 and its two-hundred day moving average price is $17.23. The firm has a market cap of $180.73 million, a PE ratio of -7.75 and a beta of 0.83. MediWound has a one year low of $7.45 and a one year high of $24.00.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.26). MediWound had a negative net margin of 99.17% and a negative return on equity of 52.49%. The company had revenue of $5.06 million during the quarter, compared to analyst estimates of $5.07 million. Sell-side analysts expect that MediWound will post -2.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MediWound

A number of institutional investors have recently added to or reduced their stakes in MDWD. Rhumbline Advisers bought a new stake in shares of MediWound during the second quarter worth $131,000. Bank of New York Mellon Corp acquired a new stake in shares of MediWound during the 2nd quarter valued at $342,000. Rosalind Advisors Inc. grew its position in MediWound by 5.7% during the 2nd quarter. Rosalind Advisors Inc. now owns 513,490 shares of the biopharmaceutical company’s stock worth $7,969,000 after acquiring an additional 27,500 shares during the last quarter. Essex Investment Management Co. LLC increased its holdings in MediWound by 241.6% in the 1st quarter. Essex Investment Management Co. LLC now owns 132,487 shares of the biopharmaceutical company’s stock worth $1,888,000 after purchasing an additional 93,705 shares in the last quarter. Finally, Janney Montgomery Scott LLC bought a new position in MediWound in the first quarter valued at about $427,000. 46.83% of the stock is currently owned by institutional investors and hedge funds.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.